/

ERAS

Erasca, Inc.Open

14.84−0.63 −4.04%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

15.25

Prev close

15.46

Day range

14.7115.58

52-week range

2.1124.28

Volume

1.12M0.25×

Mkt cap

5.19B

P/E ttm

—

Fwd P/E

-23.81

EPS ttm

-0.9500

Div yield

0.00%

Earnings

—

From 52w high

−38.90%

Price Chart

Yahoo Finance · delayed

ERASOct 13, 2026O 15.25H 15.58L 14.71C 14.84−0.63 (−4.04%)Vol 1.12M

SMA 5016.44
SMA 20014.38

1Y change +515.56% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ERAS Erasca, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +3.74%
1 month: −6.58%
3 months: −23.92%
6 months: −16.89%
Year to date: +298.79%
1 year: +518.12%

Valuation & ownership

Market cap: 5.19B
Enterprise value: 5.18B
P/E (ttm): —
Forward P/E: -23.81
PEG ratio: —
Price / book: 12.81
Price / sales (ttm): —
EV / EBITDA: -35.08
EPS (ttm): -0.9500
EPS (forward): -0.6232
Beta (5y monthly): 0.62
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 349.76M
Float: 255.21M
Short % of float: 11.18%
Short ratio (days): 7.32
Held by insiders: 5.96%
Held by institutions: 86.21%
Avg volume (3m): 4.47M
50-day average: 16.50
200-day average: 14.33
52-week change: +518.12%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 45.6
vs 50-day SMA: −9.75%
vs 200-day SMA: +3.15%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.73%
Realised vol (20d, ann.): 67.4%
From 52-week high: −38.90%
From 52-week low: +604.75%

ANR

Analyst Consensus

9 analysts

Consensus

—

Mean target

24.11

+62.53% implied

Low 20.00Median 22.00High 33.00

Recommendation trend

Now7 / 2 / 0
1m ago8 / 2 / 0

DES

About Erasca, Inc.

Yahoo Finance profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 103
Headquarters: San Diego, CA, United States
Website: erasca.com
Officers: Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO
Dr. David M. Chacko M.D.

SEAS

Seasonality · ERAS

2021–2026 · monthly returns

Strongest month Jul +18.98%Weakest month Jan −19.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	182.5	30.0	18.4	-34.2	20.6	42.7	-0.9	-1.5	-18.0	1.2			+298.8%
2025	-24.7	-27.5	0.0	6.6	-4.1	-9.3	11.4	11.0	38.9	11.0	31.0	17.4	+48.2%
2024	-21.6	42.5	-13.4	-2.4	25.4	-6.3	33.5	-8.3	-5.5	-5.1	10.4	-12.2	+17.8%
2023	-7.2	-10.0	-16.4	-8.3	-1.8	1.8	-4.3	-1.9	-23.9	17.3	-26.4	25.3	−50.6%
2022	-23.9	4.6	-30.6	-15.3	-25.5	2.8	35.4	19.6	-13.5	4.7	-7.6	-42.9	−72.3%
2021								13.9	-11.3	-6.8	-28.4	10.0	−25.8%

INSD

Insider Activity · ERAS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

80K shares

Sells, 6 months

80K shares

Net shares

Net change in insider shares

0.00%

Date	Insider	Transaction	Shares	Value
Mar 31, 2026	Garner Ebun SOfficer	Sale at price 16.40 per share.	80K	$1.31M
Mar 31, 2026	Garner Ebun SOfficer	Conversion of Exercise of derivative security at price 1.70 per share.	80K	$136.00K
Mar 3, 2026	Morris Shannon R. M.D., Ph.D.Officer	Sale at price 15.04 per share.	20K	$300.76K
Mar 3, 2026	Morris Shannon R. M.D., Ph.D.Officer	Conversion of Exercise of derivative security at price 1.70 per share.	20K	$34.00K
Jan 6, 2026	Garner Ebun SGeneral Counsel	Sale at price 5.59 per share.	120K	$670.81K
Jan 6, 2026	Garner Ebun SGeneral Counsel	Conversion of Exercise of derivative security at price 1.70 per share.	120K	$204.00K
Dec 14, 2025	Garner Ebun SGeneral Counsel	Stock Award(Grant) at price 3.43 per share.	3.9K	$13.38K
May 22, 2025	Multani Pratik SDirector	Stock Gift at price 0.00 per share.	6.2K	—

13F

Investors Holding ERAS

latest 13F filings of 29 followed managers

Investors holding ERAS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$25.1M	0.03%	1.37M	−2.1%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ERAS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ERAS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Erasca, Inc.

Seasonality · ERAS

Insider Activity · ERAS

Congress Trades · ERAS

Investors Holding ERAS

Investors Holding ERAS

Congress Trades · ERAS

Insider Activity · ERAS

Seasonality · ERAS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Erasca, Inc.

Financial Snapshot

Earnings & Dividends

News